AHA STAT - An American Hospital Association Blog
Facebook Twitter LinkedIn Google+ Pinterest RSS


A vital safety-net program

By AHA STAT Staff
July 20, 2017

The exorbitant cost of many prescription drugs threatens providers’ ability to provide life-saving medications for millions of Americans.

That is why the 340B Drug Pricing Program, which provides discounts on drugs to some health care providers who serve large numbers of low-income and uninsured patients, is so critical.

Efforts to scale back or eliminate it are the wrong prescription for advancing the health of underserved communities, and vulnerable patients would be the ones... read more

Topic: Access and Coverage
Tags: 340B, access

Preserve the 340B program

By Tom Nickels
March 9, 2017

Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system.

One program that has a 25-year track record of improving access to medications and health care services for people in vulnerable communities is the 340B Drug Pricing Program.

It requires pharmaceutical manufacturers participating in Medicaid to sell many outpatient drugs at discounted prices to health care organizations... read more

Topic: Advocacy and Public Policy
Tag: 340B

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

By Tom Nickels
May 17, 2016

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits – discussing how they can continue to disparage a program with a 25-year history of increasing access to medications and health care services for people in vulnerable communities.

Let’s... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

By Tom Nickels
March 8, 2016

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program with a 25-year history of increasing access to medications and health care services for people in vulnerable communities in order to add to record profits of drug... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Protect Patients. Preserve 340B.

By AHA STAT Staff
November 19, 2015

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing government spending, some want changes that would weaken the program.   

340B hospitals continue to help care for low-income and uninsured patients. That is why the AHA sponsored... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

340B Proposals Would Jeopardize Hospitals' Ability to Serve Vulnerable Patients

By Tom Nickels
October 27, 2015

The 340B Drug Pricing Program has a strong track record of helping to combat high prescription drug prices and increase access to vital medicines and comprehensive health care services for our nation’s most vulnerable individuals.

However, we are concerned that recent policy changes proposed by the Health Resources and Services Administration (HRSA), the federal agency responsible for administering the 340B program, would jeopardize eligible hospitals’ ability to care for... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, drug prices

GAO Report Misses Mark on 340B Program

By Tom Nickels
July 7, 2015

A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities. Simply put, the GAO report misses the mark.

The AHA, along with the Department of Health and Human Services (HHS), has expressed concerns about the methodology GAO used to conclude... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access

AHA responds to latest effort by pharmaceutical industry to disparage 340B program

By Linda Fishman
June 9, 2015

A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.

For more than 20 years, the 340B Drug Pricing Program has provided financial relief from high prescription drug costs allowing eligible hospitals to stretch limited federal resources to reduce drug costs and expand health services to patients.

Yesterday’s report says... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access

Hospital Priorities for the New Congress

By Erik Rasmussen
January 13, 2015

The newly-sworn-in 114th Congress kicked off legislating on a slew of topics and priorities. Similarly, the American Hospital Association is advocating on Capitol Hill for issues affecting the nation’s hospitals. Since the country is in the midst of football playoffs, we will tackle these hospital priorities from both an offensive strategy and defensive strategy. On the offensive front – hospitals hope to see the 114th Congress reform the Recovery Audit Contractor (RAC) program and... read more

Topic: Advocacy and Public Policy
Tags: 340B, site neutral payment, RACs

Setting the Record Straight on 340B

By Linda Fishman
December 8, 2014

A new report by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.

For more than 20 years, the 340B Drug Pricing Program has provided financial relief from high prescription drug costs allowing eligible hospitals to stretch limited federal resources to reduce drug costs and expand health services to patients.

Financed by a group claiming to... read more

Topic: Access and Coverage
Tag: 340B
 

Search

Twitter

About AHA

Membership

Member Constituency Sections

Key Relationships

News Center

Performance Improvement

Advocacy Issues

Products & Services

Publications

Research & Trends

Locations

155 N. Wacker Dr.
Chicago, Illinois 60606
312.422.3000

800 10th Street, N.W.
Two CityCenter, Suite 400
Washington, DC 20001-4956
202.638.1100

1.800.424-4301